Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series

C Droitcourt (1, 2, 3) , Henri Adamski (1) , A Polat (1) , E Polard (1) , M Kerjouan (1) , B Arnouat (1) , M Le Garrec (1) , E Oger (3, 1) , A Dupuy (1, 3) , S Jouneau (1, 4)

1 CHU Pontchaillou [Rennes]
2 CIC - Centre d'Investigation Clinique [Rennes]
3 REPERES - Recherche en Pharmaco-épidémiologie et Recours aux Soins
4 Irset - Institut de recherche en santé, environnement et travail

The oral antifibrotic agent, pirfenidone (PFD), 5-methyl-l-phenyl-[1H]-pyridine, is used to treat idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. In trials, PFD reduces disease progression and decreases mortality. The most common adverse events of PFD are skin manifestations (25%), described as photosensitivity or rash, but they are not well characterized. The objective of the present real-life study was to address the question of skin manifestations in patients treated with PFD for IPF.

Domains: Life Sciences [q-bio]; Human health and pathology; Dermatology

C Droitcourt, Henri Adamski, A Polat, E Polard, M Kerjouan, et al.. Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series. British Journal of Dermatology, 2018, 178 (3), pp.e222-e223. ⟨10.1111/bjd.16016⟩. ⟨hal-01771415⟩